Brought to you by 
BioLineRx gets IBD candidate from Yissum
14 Nov 2008
Executive Summary
Hebrew University's tech transfer entity Yissum has licensed BioLineRx exclusive worldwide rights to develop and commercialize a new drug candidate, BL5040, for inflammatory diseases.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BioLineRx gets IBD candidate from Yissum
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice